Parkinson's disease (PD) has joined the list of disorders that are affected by the gut microbiome. In studies reported in the Dec. 1, 2016, issue of Cell, researchers showed that signals from the gut microbiome affected the level of neuroinflammation and the degree of motor dysfunction in an animal model of PD.
DUBLIN – PCSK9 inhibitors are as good as but no better than statins in reducing the risk of cardiovascular events in patients with cardiovascular disease, according to a large-scale Mendelian randomization study published this week in the New England Journal of Medicine. more »
- Astrazeneca takes Bicycle to work in potential $1B multitarget collaboration
- Heat Biologics shares melt as cancer vaccine disappoints
- Cures supporters pledging to keep promises as bill heads to Senate
- Industry lauds Cures bill; critics take aim ahead of Senate review
- Going up? Bluebird BCMA phase I with CAR T in MM...
- Innovent's $260M private financing is China's largest ever for a biopharma
- Smog alert: Pollution around Beijing halts drug manufacturing
- Singapore's Cellresearch advances wound healing stem cell treatment
- Privacy in the genomics age: A unique ethics debate in Islamic world
- After IPO, new deals, Adalta entering clinic wit...
Last year's approvals of hemophilia A therapies Nuwiq (simoctocog alfa) from Octapharma AG, of Lachen, Switzerland, and long-acting Adynovate (antihemophilic factor [recombinant], pegylated) from Baxalta Inc. (now part of Shire plc) capped a two-year rush of products to treat bleeding disorders following a long dry spell in the space. As the American Society of Hematology (ASH) annual meeting prepares to kick off this week in San Diego, analysts are handicapping the next generation of treatments, designed to extend therapeutic benefits from days to weeks, and watching for clues on the trajectory of potentially curative gene therapies.
"Basically, it's not easy to define what will serve humanity."
So said Yoshinori Ohsumi, honorary professor at the Tokyo Institute of Technology, after winning the 2012 Kyoto Prize in Life Sciences for his research.
The Nobel Assembly followed suit in recognizing the importance of Ohsumi's work, awarding him the 2016 Nobel Prize in Physiology or Medicine to "for his discoveries of mechanisms for autophagy."READ MORE »
- First steps taken toward neutralizing Zika virus »
- Medicine's future is precise, if still uncertain »
- Quorum sensing controls adaptive immunity via CRISPR »
- Tau phosphorylation inhibits plaque toxicity in AD mice »
- Drug shows promise in preventing pre-term birth in mice »
- Cachexia is linked to immunotherapy failure »
- Circuit-specific receptor targeting fights epilepsy »
- Bacterial metabolite shows activity in breast cancer »
- Stimulating, blocking rapid-acting estrogen receptor both beneficial »
- Time for fa-la-la with BioWorld’s 10th annual Holiday Gift GuideDecember 02, 2016 | 8:43 PM | Posted by: Marie Powers
- Biotech’s biggest protesters are turning into its supporters November 30, 2016 | 10:58 PM | Posted by: Amanda Lanier
- Sex and drugs: Something doesn’t ‘Addyi’ upNovember 04, 2016 | 10:35 PM | Posted by: Randy Osborne
- Rules of the PAP road not always clear, even to seasoned travelersOctober 25, 2016 | 11:37 PM | Posted by: Marie Powers
- Left on the garbage heap of the 114th Congress?September 02, 2016 | 4:57 PM | Posted by: Mari Serebrov
Partners in Focus
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter